Lamy(OTC) LMMY

L A M Y first offered a video game teaching kids about money. Now, it develops biotechnology treatments for cancer. Its focus shifted after acquiring a clinical-stage biotech company in 2025.

Products and Services

• TwoPlus1 (100% of revenue in 2024): Educational video game teaching financial skills to children and teenagers.
• eLearning Marketplace: Platform for digital educational and gaming content, targeting young learners.
• Exosome-Based Therapeutics (0% of revenue in 2025): Clinical-stage biotechnology treatments for cancer, targeting healthcare providers and researchers.

Growth and Expansion

• Acquired Exousia AI in November 2025, shifting focus to biotechnology and oncology therapeutics.
• Amended articles of incorporation in January 2026, increasing authorized shares and creating Series X Preferred Stock.
• Issued a $250,000 convertible promissory note to GBII Partners Inc. in January 2026 for additional funding.

What Makes L A M Y Stand Out

The company transitioned from digital education to clinical-stage biotechnology in late 2025. It now focuses on developing exosome-based cancer therapies, a niche area in biotech. L A M Y operates with minimal staff and relies on external funding for growth.

Five Things You Need to Know

• Revenue was $0 in QQ1 2025, down 100% from QQ1 2024.
• Net loss was $31,814 in QQ1 2025, down 632.9% year-over-year.
• Cash at period end was $0 as of November 30, 2025.
• Accumulated deficit reached $288,623 by November 30, 2025.
• Market cap was $3.89 million with 2 full-time employees in March 2026.

Bottom Line

L A M Y rapidly shifted from educational gaming to biotechnology in 2025. The company now faces new challenges as it develops cancer therapies with limited resources.